- Email: [email protected]
Neutrox Found Not Acceptable by Council on Dental Therapeutics
Dental Therapeutics
J.A.D.A., Vol. 34, May 15, 1947 . . . 703
sensitization from sulfathiazole gum is not high. If this preparation were an essential agent for the treatment of den tal infections, the risk of sulfonamide reactions might be justified. However, the evidence is not yet at hand to prove that sulfathiazole gum is superior to other methods of treatment which do not have the potential hazard of serious sen sitization reactions, and consequently the
Council has found this product unaccept able for Accepted Dental Remedies. Further studies of the value and safety of sulfathiazole gum in dentistry are now under way and will be considered care fully by the Council upon their comple tion. In the event that the results should justify revision of the Council’s attitude toward this product, it will be so reported in the Council’s section of t h e j o u r n a l .
NEUTROX FOUND NOT ACCEPTABLE BY C O U N C IL ON DENTAL THERAPEUTICS
T h e Vick Chemical Company, distrib
utor of Neutrpx, states that the com position of Neutrox is as follows: sodium perborate monohydrate (U.S.P. dehydrated), 30 per cent; monocalcium phosphate, 30 per cent; tricalcium phos phate, 23.87 per cent; magnesium car bonate, 10 per cent; saccharin soluble, 0.3 per cent; sodium chloride, 2 per cent; menthol, 0.33 per cent; oil of pepper mint, 0.5 per cent; methyl salicylate, 0.65 per cent; oil of anise, 0.042 per cent; liquid petrolatum, light, 1.81 per cent, and sodium lauryl sulfoacetate, 0.5 per cent. The firm has agreed to keep the Coun cil on Dental Therapeutics informed of all changes in the composition of Neu trox. Neutrox is covered by U. S. Patent 2,094,671 and U. S. Trade-Mark 355,9 *9' Neutrox is a mixture of sodium per borate monohydrate and acid calcium phosphate together with ingredients usu ally found in dentifrices. Magnesium carbonate and tricalcium phosphate are apparently included for their abrasive cleansing effect. The Council report.
has
authorized
publication
of
this
Neutrox currently is advertised only to dentists. Following are some of the claims made for the product: “ It is a new and more efficacious way to treat gingival infections.” “ It supplements your office treatments.” “ It is evidence of your own specialized knowledge.” “ It promotes better patient cooperation.” “ Safe oxygen therapy for daily home use . . . absolutely no bum.” These statements appear to encourage prolonged daily home use of a dentifrice which contains an oxidizing agent. The Council does not accept such agents be cause it does not have evidence to show that their use is warranted or beneficial or that they are entirely free from irritat ing effects. Neutrox is unacceptable for Accepted Dented Remedies because therapeutic claims for the product are not adequately supported by scientific evidence which is available to the Council, and daily use of a dentifrice which contains a strong oxidizing agent does not appear to be warranted or desirable. As a matter of general policy, all decisions of the Council are subject to revision in the light of new scientific evidence.
J.A.D.A., Vol. 34, May 15, 1947 . . . 703
sensitization from sulfathiazole gum is not high. If this preparation were an essential agent for the treatment of den tal infections, the risk of sulfonamide reactions might be justified. However, the evidence is not yet at hand to prove that sulfathiazole gum is superior to other methods of treatment which do not have the potential hazard of serious sen sitization reactions, and consequently the
Council has found this product unaccept able for Accepted Dental Remedies. Further studies of the value and safety of sulfathiazole gum in dentistry are now under way and will be considered care fully by the Council upon their comple tion. In the event that the results should justify revision of the Council’s attitude toward this product, it will be so reported in the Council’s section of t h e j o u r n a l .
NEUTROX FOUND NOT ACCEPTABLE BY C O U N C IL ON DENTAL THERAPEUTICS
T h e Vick Chemical Company, distrib
utor of Neutrpx, states that the com position of Neutrox is as follows: sodium perborate monohydrate (U.S.P. dehydrated), 30 per cent; monocalcium phosphate, 30 per cent; tricalcium phos phate, 23.87 per cent; magnesium car bonate, 10 per cent; saccharin soluble, 0.3 per cent; sodium chloride, 2 per cent; menthol, 0.33 per cent; oil of pepper mint, 0.5 per cent; methyl salicylate, 0.65 per cent; oil of anise, 0.042 per cent; liquid petrolatum, light, 1.81 per cent, and sodium lauryl sulfoacetate, 0.5 per cent. The firm has agreed to keep the Coun cil on Dental Therapeutics informed of all changes in the composition of Neu trox. Neutrox is covered by U. S. Patent 2,094,671 and U. S. Trade-Mark 355,9 *9' Neutrox is a mixture of sodium per borate monohydrate and acid calcium phosphate together with ingredients usu ally found in dentifrices. Magnesium carbonate and tricalcium phosphate are apparently included for their abrasive cleansing effect. The Council report.
has
authorized
publication
of
this
Neutrox currently is advertised only to dentists. Following are some of the claims made for the product: “ It is a new and more efficacious way to treat gingival infections.” “ It supplements your office treatments.” “ It is evidence of your own specialized knowledge.” “ It promotes better patient cooperation.” “ Safe oxygen therapy for daily home use . . . absolutely no bum.” These statements appear to encourage prolonged daily home use of a dentifrice which contains an oxidizing agent. The Council does not accept such agents be cause it does not have evidence to show that their use is warranted or beneficial or that they are entirely free from irritat ing effects. Neutrox is unacceptable for Accepted Dented Remedies because therapeutic claims for the product are not adequately supported by scientific evidence which is available to the Council, and daily use of a dentifrice which contains a strong oxidizing agent does not appear to be warranted or desirable. As a matter of general policy, all decisions of the Council are subject to revision in the light of new scientific evidence.